Search Results
204 items found for "Systemic treatment"
- Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota..
(IELs) are thought to calibrate glucagon-like peptide 1 (GLP-1) bioavailability, thereby regulating systemic anti-inflammatory actions of GLP-1RAs require the gut IEL GLP-1R to selectively restrain local and systemic GLP-1R activation in gut IELs to modulation of microbiota composition and control of intestinal and systemic
- Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024
winners of its Transforming Cancer Therapeutics grant, which focuses on developing life-changing cancer treatments Sleep-Deprived Healthy Volunteers Cumulus raising $50M, spinning GPR68 small molecules into GIO New treatments , Endocrinology, and Taste CRTC1 in Mc4r-expressing cells is required for peripheral metabolism and systemic
- 📰 GPCR Weekly News, October 30 to November 4, 2023
pathways via MADD, a Rab11A effector that activates Rab27B Targeting of insulin receptor endocytosis as a treatment TRPV4 to suppress astrocyte activation and to relieve neuropathic pain GPCRs in Oncology and Immunology Systems Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment
- 📰 GPCR Weekly News, May 22 to 28, 2023
Structural genomics of the human dopamine receptor system Structural Insights into Molecular Recognition Quarter 2023 Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment
- Feeder or trigger – CCR2 as a scavenger and regulator of cell migration
Although less characterized, canonical chemokine receptor systems have been also shown to not only directly However, it is important to note that this scavenging role does not occur in all chemokine receptor systems In monocytes and dendritic cells exposed to treatments mimicking inflammation, CCR1, CCR2, and CCR5 switch
- Recurrent hypoglycemia increases hepatic gluconeogenesis without affecting glycogen metabolism or sy
2022 Recurrent hypoglycemia increases hepatic gluconeogenesis without affecting glycogen metabolism or systemic Finally, we conducted epinephrine tolerance test to investigate systemic glycemic excursions to counterregulatory
- VAMP2: a crucial player in the delivery of MOR to the synapse
Therefore, their comprehension is essential for developing new treatments for these disorders and advancing our understanding of the brain and nervous system.
- 📰 GPCR Weekly News, January 8 to 14, 2024
small molecules against cannabinoid 2 receptor (CB2R) Ketone bodies as chemical signals for the immune system Achieves Milestone: Randomisation Concludes in Largest-Ever Phase 2b Clinical Trial for Cannabis Addiction Treatment
- 📰 GPCR Weekly News, June 26 to July 2, 2023
and function of the lactate receptor GPR81/HCAR1 in the brain: a putative therapeutic target for the treatment Internal and external modulation factors of the orexin system (REVIEW).
- 📰 GPCR Weekly News, May 27 to June 2, 2024
more ERNEST COST action overview on the (patho)physiology of GPCRs and orphan GPCRs in the nervous system Announces Positive Initial Findings At Endo 2024 For Atumelnant In Two Ongoing, Open-Label Studies For The Treatment
- 📰 GPCR Weekly News, April 15 to 21, 2024
pluripotent stem cell-derived nociceptive-like neurons Characterization of myoinhibitory peptide signaling system Aelis Farma announces the Last Patient, Last Visit in its clinical phase 2b trial with AEF0117 for the treatment
- GPCR Buzz of the Week | Sep 23 - 29, 2024
powerful applications of new cellular assays to determine GPCR ligand behavior in different functional systems Initiation of Phase 1 Clinical Trial with SEP-786, a Novel Oral Small Molecule PTH1R Agonist for the Treatment
- Trevena Reports Second Quarter 2022 Results and Provides Business Update
focused on the development and commercialization of novel medicines for patients with central nervous system
- Advancements in G protein-coupled receptor biosensors to study GPCR-G protein coupling
Enzymatic and cellular signalling biosensors are used to decipher the activities of complex biological systems
- Latrophilin-1 drives neuron morphogenesis and shapes chemo- and mechanosensation-dependent ...
Latrophilins are highly conserved Adhesion GPCRs playing essential roles in the mammalian nervous system Latrophilin-1 acts in trans to mediate morphogenesis of sensory structures in the C. elegans nervous system
- Exciting GPCR Events for Next Year! + GPCR Weekly Rocket Launch ⦿ Oct 28 - Nov 3, 2024
al. for their outstanding study on Class B1 GPCRs: insights into multireceptor pharmacology for the treatment , Andrew Lawrence , et al. for their remarkable analysis on Targeting muscarinic receptors for the treatment neutrophils Mechanistic exploration of bioactive constituents in Gnetum gnemon for GPCR-related cancer treatment family: Opportunities and challenges Class B1 GPCRs: insights into multireceptor pharmacology for the treatment receptor as a therapeutic target for substance use disorders Targeting muscarinic receptors for the treatment
- GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!
powerful applications of new cellular assays to determine GPCR ligand behavior in different functional systems Initiation of Phase 1 Clinical Trial with SEP-786, a Novel Oral Small Molecule PTH1R Agonist for the Treatment
- GPCRS: AN ODYSSEY FROM STRUCTURE, SIGNALING AND REGULATION TO THERAPEUTICS
protein-coupled receptors (GPCRs) act as molecular sensors central to all cellular and physiological systems complexity raises further fundamental questions and challenges in the study of GPCR action in multiple systems
- Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...
focused on the development and commercialization of novel medicines for patients with central nervous system
- Modulation of Striatal Adenosinergic Function by HTL0041178, a Selective GPR52 Agonist
This work highlights an important interplay between the adenosinergic and dopaminergic systems and suggests
- Neurotransmitters: Potential Targets in Glioblastoma
multiforme (GBM), a type of the most lethal brain tumor, has remained a formidable challenge in terms of its treatment the normal neural and the GBM microenvironments, and discuss potential targeted drugs used for GBM treatment
- N-terminal alterations turn the gut hormone GLP-2 into an antagonist with gradual loss of GLP-2 ...
1 receptor interaction "Background and purpose: To fully elucidate the regulatory role of the GLP-2 system
- G protein-coupled receptor signaling: transducers and effectors
explore the signaling pathways, dynamic structures, and physiological relevance in the cardiovascular system
- Structural view of G protein-coupled receptor signaling in the retinal rod outer segment
Although hypothetical, the reconstruction of the rod phototransduction system highlights the potential
- The sixth transmembrane region of a pheromone G-protein coupled receptor, Map3, is implicated in ...
Although such pheromone/receptor systems are likely to function in both mate choice and prezygotic isolation might reflect the significantly distinct stringency/flexibility of their respective pheromone/receptor systems
- Emerging approaches for decoding neuropeptide transmission
high-resolution techniques to investigate peptidergic transmission and expression throughout the brain in model systems
- Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ...
focused on the development and commercialization of novel medicines for patients with central nervous system
- Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...
small molecule drugs known as allosteric modulators is being explored for treating central nervous system